The Circulating Pool of Functionally Competent NK and CD8+ Cells Predicts the Outcome of anti-PD1 Treatment in Advanced NSCLC

Cancer development and progression are complex and dynamic processes regulated by non-random adaptations resulting from a continuous interaction between the tumor and its microenvironment. A delicate although active balance is established with the host in which cancer editing through immune checkpoints involvement ultimately triggers anti- or pro-tumorigenic contexts. In this scenario, specific inhibitors of several checkpoint related pathways have received particular attention due to an unparalleled efficacy in advanced hematologic and solid malignancies, including non-small cell lung cancer (NSCLC) [1 –3].

Source: Lung Cancer - November 29, 2018 Category: Cancer & Oncology Authors: Giulia Mazzaschi, Francesco Facchinetti, Gabriele Missale, Diana Canetti, Denise Madeddu, Alessandra Zecca, Michele Veneziani, Francesco Gelsomino, Matteo Goldoni, Sebastiano Buti, Paola Bordi, Franco Aversa, Andrea Ardizzoni, Federico Quaini, Marcello Ti Source Type: research